Holen Sie sich die Stockscreener-App
5.38
2.87%
0.15
Handel nachbörslich:
5.38
Schlusskurs vom Vortag:
$5.23
Offen:
$5.28
24-Stunden-Volumen:
380.37K
Relative Volume:
0.37
Marktkapitalisierung:
$511.09M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-75.43M
KGV:
-4.4095
EPS:
-1.2201
Netto-Cashflow:
$-72.75M
1W Leistung:
+2.28%
1M Leistung:
+0.56%
6M Leistung:
-16.33%
1J Leistung:
+228.05%
1-Tages-Spanne:
$5.27
$5.68
1-Wochen-Bereich:
$5.12
$5.71
52-Wochen-Spanne:
$1.345
$7.44
Zura Bio Ltd Stock (ZURA) Company Profile
Firmenname
Zura Bio Ltd
Sektor
Branche
Telefon
858-247-0520
Adresse
4225 EXECUTIVE SQUARE, LA JOLLA
Compare ZURA vs VRTX, REGN, ARGX, RVMD, ALNY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ZURA
Zura Bio Ltd
|
5.38 | 496.84M | 0 | -75.43M | -72.75M | -1.2201 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Zura Bio Ltd Stock (ZURA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-09 | Eingeleitet | Wedbush | Outperform |
| 2024-11-04 | Eingeleitet | Leerink Partners | Outperform |
| 2024-09-05 | Eingeleitet | H.C. Wainwright | Neutral |
| 2024-05-03 | Eingeleitet | Piper Sandler | Overweight |
| 2023-10-10 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2023-08-25 | Eingeleitet | Oppenheimer | Outperform |
| 2023-06-22 | Eingeleitet | Guggenheim | Buy |
| 2023-06-14 | Eingeleitet | Chardan Capital Markets | Buy |
| 2023-05-24 | Eingeleitet | Raymond James | Strong Buy |
Alle ansehen
Zura Bio Ltd Aktie (ZURA) Neueste Nachrichten
Zura Bio Ltd (ZURA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Zura Bio Ltd (ZURA) Cash Flow - TradingKey
Zura Bio Ltd (ZURA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
ZURA|Zura Bio Ltd|Price:5.230|Chg%:-0.060 - TradingKey
Zura Bio Ltd (ZURA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Zura Bio Ltd (ZURA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
TradingKey - TradingKey
Marlyn Teresa Mathew Net Worth (2026) - GuruFocus
William Blair Starts Zura Bio (ZURA) at Outperform - Yahoo Finance
ZURA Initiated Coverage by William Blair -- Rating Set to Outper - GuruFocus
What's Going on With Zura Bio Stock Wednesday?Zura Bio (NASDAQ:ZURA) - Benzinga
Zura Bio navigates growth path amid biotech volatility - Ad-hoc-news.de
William Blair initiates Zura Bio stock with outperform rating By Investing.com - Investing.com Nigeria
William Blair initiates Zura Bio stock with outperform rating - Investing.com
William Blair Initiates Zura Bio(ZURA.US) With Buy Rating - Moomoo
Zura Bio stock. Company profile and listing context. - Ad-hoc-news.de
Zura Bio’s Tibulizumab: First Dual BAFF & IL-17 Bispecific Antibody for Complex Autoimmune Diseases, Advancing in Phase 2 Trials – Minichart - Minichart
Jessica Chen - White & Case LLP
Zura Bio updates corporate presentation; tibulizumab Phase 2 toplines, $225.6M cash (Mar 31, 2026) - TradingView
Zura Bio (NASDAQ: ZURA) furnishes updated corporate presentation for investors - Stock Titan
Guggenheim Maintains Zura Bio(ZURA.US) With Buy Rating, Maintains Target Price $15 - Moomoo
We're Hopeful That Zura Bio (NASDAQ:ZURA) Will Use Its Cash Wisely - simplywall.st
Zura Bio completes enrollment in tibulizumab trials By Investing.com - Investing.com South Africa
ZURA Financial Update: Cash Position and Operational Outlook - GuruFocus
Zura Bio completes Phase 2 trial enrollment for tibulizumab in hidradenitis suppurativa - Traders Union
Zura Bio clears enrollment targets in two Phase 2 studies, adds a third - Stock Titan
Zura Bio (ZURA) VP details share, RSU and option holdings - Stock Titan
Zura Bio | 4: Statement of changes in beneficial ownership of securities-Director Jarrett Jennifer - Moomoo
Zura Bio (NASDAQ: ZURA) director receives grant of 51,000 share options - Stock Titan
Zura Bio (ZURA) director awarded 51,000 share options at $3.62 - Stock Titan
Zura Bio (ZURA) director receives grant of 51,000 stock options - Stock Titan
Zura Bio (ZURA) director Amit Munshi granted 51,000 share options at $3.62 - Stock Titan
Zura Bio (ZURA) director Daniel Becker receives 51,000 share options at $3.62 - Stock Titan
Director at Zura Bio (NASDAQ: ZURA) granted 51,000 stock options - Stock Titan
Zura Bio (ZURA) director receives 51,000 share options at $3.62 strike price - Stock Titan
Zura Bio StockSaturday look at the business model and pipeline - AD HOC NEWS
Zura Bio (NASDAQ: ZURA) investors approve board slate, auditor and 2023 equity plan changes - Stock Titan
Zura Bio Ltd (ZURA) Institutional Confidence - TradingKey
Zura Bio Ltd (ZURA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Zura Bio Ltd (ZURA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Zura Bio Ltd (ZURA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Zura Bio Ltd (ZURA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Zura Bio Ltd stock (KYG989201089): Pipeline update and capital raise reshape the story - AD HOC NEWS
Here's Why We're Not Too Worried About Zura Bio's (NASDAQ:ZURA) Cash Burn Situation - Yahoo Finance
ZURAZura Bio Ltd Stock Price and Quote - Finviz
Zura Bio (NASDAQ: ZURA) discloses resignation of director Someit Sidhu - Stock Titan
Zura Bio Ltd stock (KYG989201089): pipeline update keeps autoimmune story in focus - AD HOC NEWS
Venrock entities report 9.99% ownership in ZURA (ZURA) - Stock Titan
Great Point Partners, Dr. Jay & Nordahl report 4.44% in ZURA (ZURA) - Stock Titan
Zura Bio reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Zura Bio stock (KYG989201089): Appoints Muzammil Mustufa as Chief Business Officer - AD HOC NEWS
Finanzdaten der Zura Bio Ltd-Aktie (ZURA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):